Illumina, Inc. (NASDAQ:ILMN) Shares Sold by Hixon Zuercher LLC

Hixon Zuercher LLC decreased its holdings in Illumina, Inc. (NASDAQ:ILMN) by 2.3% in the 3rd quarter, HoldingsChannel.com reports. The fund owned 9,313 shares of the life sciences company’s stock after selling 216 shares during the quarter. Hixon Zuercher LLC’s holdings in Illumina were worth $1,215,000 as of its most recent SEC filing.

A number of other large investors have also modified their holdings of ILMN. Industrial Alliance Investment Management Inc. acquired a new position in Illumina during the 2nd quarter worth $34,000. Versant Capital Management Inc boosted its stake in shares of Illumina by 292.9% in the 2nd quarter. Versant Capital Management Inc now owns 330 shares of the life sciences company’s stock valued at $34,000 after buying an additional 246 shares during the period. Massmutual Trust Co. FSB ADV boosted its stake in shares of Illumina by 65.1% in the 3rd quarter. Massmutual Trust Co. FSB ADV now owns 426 shares of the life sciences company’s stock valued at $56,000 after buying an additional 168 shares during the period. Focused Wealth Management Inc purchased a new stake in shares of Illumina during the third quarter worth approximately $63,000. Finally, nVerses Capital LLC acquired a new stake in Illumina in the third quarter valued at approximately $65,000. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the stock. Daiwa Capital Markets upgraded shares of Illumina from a “neutral” rating to a “buy” rating and raised their price objective for the company from $120.00 to $154.00 in a report on Friday, August 16th. Piper Sandler decreased their price target on Illumina from $200.00 to $195.00 and set an “overweight” rating for the company in a report on Tuesday, August 13th. Scotiabank dropped their price objective on Illumina from $176.00 to $164.00 and set a “sector outperform” rating on the stock in a report on Thursday, August 15th. JPMorgan Chase & Co. boosted their target price on Illumina from $125.00 to $140.00 and gave the stock a “neutral” rating in a research note on Tuesday. Finally, Hsbc Global Res raised Illumina from a “hold” rating to a “strong-buy” rating and set a $180.00 price target for the company in a report on Thursday, October 17th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating, fourteen have issued a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $161.50.

Illumina Stock Up 1.0 %

ILMN stock opened at $154.96 on Wednesday. The stock has a market capitalization of $24.69 billion, a PE ratio of -15.56 and a beta of 1.13. The company has a fifty day moving average of $136.87 and a 200-day moving average of $122.92. The company has a debt-to-equity ratio of 1.04, a quick ratio of 0.86 and a current ratio of 1.11. Illumina, Inc. has a one year low of $89.00 and a one year high of $156.66.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings results on Monday, November 4th. The life sciences company reported $1.14 earnings per share for the quarter, topping analysts’ consensus estimates of $0.88 by $0.26. Illumina had a negative net margin of 68.73% and a positive return on equity of 3.08%. The business had revenue of $1.08 billion for the quarter, compared to analysts’ expectations of $1.08 billion. During the same period in the prior year, the company posted $0.33 EPS. The business’s revenue for the quarter was down 3.5% on a year-over-year basis. As a group, analysts expect that Illumina, Inc. will post 3.62 EPS for the current year.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.